Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.97000.0000 (0.00%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.9700
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.9700 - 2.9700
52-week range0.9500 - 3.8300
Avg. volume84
Market cap212.604M
Beta (5Y monthly)2.16
PE ratio (TTM)N/A
EPS (TTM)-1.4100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights11/30/202371,751,20177,686,109 For further information on Cellectis, please contact: Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, Investor Relations contacts: Arthur Stril, Chief Business Off

  • GlobeNewswire

    Cellectis’ Shareholders Meeting to be Held on December 22, 2023

    NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the a

  • GlobeNewswire

    Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

    Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such investment. NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investm